Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.

abstract：:Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (...

journal_title：Clinical pharmacokinetics

authors： Rosario M,Dirks NL,Milch C,Parikh A,Bargfrede M,Wyant T,Fedyk E,Fox I

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:Duloxetine, a selective serotonin (5-hydroxytryptamine) and norepinephrine reuptake inhibitor, has been approved since 2004 for the treatment of adults with major depressive disorder (MDD). It is currently not approved for use in pediatric patients (aged <18 years) with MDD. The clinical development program ...

journal_title：Clinical pharmacokinetics

authors： Lobo ED,Quinlan T,Prakash A

更新日期：2014-08-01 00:00:00

abstract：:Various pharmacokinetic models, both simple and complex, have been developed to describe the way in which the rate of hepatic elimination of drugs depends on hepatic blood flow, hepatic intrinsic clearance and unbound fraction of drug in blood. A model is necessary because it is not possible to measure the average blo...

journal_title：Clinical pharmacokinetics

authors： Morgan DJ,Smallwood RA

更新日期：1990-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment. METHODS:Cross-sectional, comparative study enrolling HIV-infected adults receiving lopinavir/rito...

journal_title：Clinical pharmacokinetics

authors： Moltó J,Valle M,Blanco A,Negredo E,DelaVarga M,Miranda C,Miranda J,Domingo P,Vilaró J,Tural C,Costa J,Barbanoj MJ,Clotet B

更新日期：2007-01-01 00:00:00

abstract：:First-pass elimination takes place when a drug is metabolised between its site of administration and the site of sampling for measurement of drug concentration. Clinically, first-pass metabolism is important when the fraction of the dose administered that escapes metabolism is small and variable. The liver is usually ...

journal_title：Clinical pharmacokinetics

authors： Pond SM,Tozer TN

更新日期：1984-01-01 00:00:00

abstract：OBJECTIVE:The aim of these studies was to determine the absolute bioavailability in healthy volunteers of inhaled fluticasone propionate (FP) administered as a single dose via the Diskhaler and Diskus powder devices, and the pharmacokinetics of inhaled FP after repeated administration via the Diskhaler device. METHODS...

journal_title：Clinical pharmacokinetics

authors： Mackie AE,McDowall JE,Falcoz C,Ventresca P,Bye A,Daley-Yates PT

更新日期：2000-01-01 00:00:00

abstract：:Bioequivalence of drug formulations plays an important role in drug development. Recently, the Biopharmaceutical Classification System (BCS) has been implemented for the purpose of waiving bioequivalence studies on the basis of the solubility and gastrointestinal permeability of drug substance. Using the rationale of ...

journal_title：Clinical pharmacokinetics

authors： Faassen F,Vromans H

更新日期：2004-01-01 00:00:00

abstract：:Thienopyridines are inactive prodrugs that are converted in vivo to active metabolites, which irreversibly bind to and inactivate platelet P2Y(12) receptors, and inhibit platelet activation and aggregation. Prasugrel is a third-generation thienopyridine, recently approved for prevention of thrombotic cardiovascular co...

journal_title：Clinical pharmacokinetics

authors： Small DS,Farid NA,Payne CD,Konkoy CS,Jakubowski JA,Winters KJ,Salazar DE

更新日期：2010-12-01 00:00:00

abstract：:Rapid drug delivery (arterial "boli') and high drug concentrations occur with nicotine inhaled in smoke. These are believed to be key elements in producing addiction to cigarettes. Preparations which reduce the rate of delivery and/or concentration of nicotine have been introduced as treatments for smoking cessation. ...

journal_title：Clinical pharmacokinetics

authors： Schneider NG,Lunell E,Olmstead RE,Fagerström KO

更新日期：1996-07-01 00:00:00

abstract：BACKGROUND:Olaparib is a first-in-class potent oral poly(ADP-ribose) polymerase inhibitor. OBJECTIVES:The aims of this analysis were to establish an integrated population pharmacokinetic (PK) model of olaparib in patients with solid tumors and to bridge the PK of olaparib between capsule and tablet formulations. METH...

journal_title：Clinical pharmacokinetics

authors： Zhou D,Li J,Bui K,Learoyd M,Berges A,Milenkova T,Al-Huniti N,Tomkinson H,Xu H

更新日期：2019-05-01 00:00:00

abstract：:Population pharmacokinetic modelling is widely used within the field of clinical pharmacology as it helps to define the sources and correlates of pharmacokinetic variability in target patient populations and their impact upon drug disposition; and population pharmacokinetic modelling provides an estimation of drug pha...

journal_title：Clinical pharmacokinetics

authors： Sherwin CM,Kiang TK,Spigarelli MG,Ensom MH

更新日期：2012-09-01 00:00:00

abstract：BACKGROUND:Fondaparinux sodium is a novel antithrombotic agent, the first of a new class of selective factor Xa inhibitors. It has favourable pharmacokinetics including 100% bioavailability, low variability and a mean terminal half-life of 17 hours for young and 21 hours for elderly healthy volunteers, enabling once-da...

journal_title：Clinical pharmacokinetics

authors： Paolucci F,Claviés MC,Donat F,Necciari J

更新日期：2002-01-01 00:00:00

abstract：:Vigabatrin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is supplied as a racemic mixture, with the S(+) enantiomer possessing pharmacological activity. [R,S]-Vigabatrin plasma concentrations can be estimated using high-performance liquid chromatographic methods. Only g...

journal_title：Clinical pharmacokinetics

authors： Rey E,Pons G,Olive G

更新日期：1992-10-01 00:00:00

abstract：:Renewed interest in vancomycin over the past decade has led to an abundance of data concerning the pharmacokinetics of vancomycin, and its dosage selection and concentration-response relationships. No definitive data exist that correlate vancomycin serum concentrations with clinical outcomes. However, inconsistencies ...

journal_title：Clinical pharmacokinetics

authors： Leader WG,Chandler MH,Castiglia M

更新日期：1995-04-01 00:00:00

abstract：OBJECTIVE:To investigate the effect of concomitant administration of dairy products on the pharmacokinetics and tolerability of moxifloxacin. DESIGN:This was a single-centre, randomised, controlled, nonblinded, 2-way crossover study in healthy volunteers. PARTICIPANTS:12 healthy men (aged 25 to 46 years) were enrolle...

journal_title：Clinical pharmacokinetics

authors： Stass H,Kubitza D

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Currently, the majority of the surgical procedures performed in paediatric hospitals are done on a day care basis, with post-operative pain being managed by caregivers at home. Pain after discharge of these post-operative children has historically been managed with oral codeine in combination ...

journal_title：Clinical pharmacokinetics

authors： Velez de Mendizabal N,Jimenez-Mendez R,Cooke E,Montgomery CJ,Dawes J,Rieder MJ,Aleksa K,Koren G,Jacobo-Cabral CO,Gonzalez-Ramirez R,Castañeda-Hernandez G,Carleton BC

更新日期：2015-10-01 00:00:00

abstract：:This article reviews the information available to assist pharmacokineticists in the prediction of metabolic drug interactions. Significant advances in this area have been made in the last decade, permitting the identification in early drug development of dominant cytochrome P450 (CYP) isoform(s) metabolising a particu...

journal_title：Clinical pharmacokinetics

authors： Bertz RJ,Granneman GR

更新日期：1997-03-01 00:00:00

abstract：:Serum concentration measurements of antibacterial agents are increasingly used to optimise drug dosage regimens. However, this approach is only justified for drugs with a low therapeutic index and poor predictability of serum concentrations, such as the aminoglycosides, chloramphenicol and vancomycin, whereas the peni...

journal_title：Clinical pharmacokinetics

authors： Wenk M,Vozeh S,Follath F

更新日期：1984-11-01 00:00:00

abstract：:Interleukins and tumour necrosis factor (TNF) are a complex group of proteins and glycoproteins able to exert pleiotropic effects with respect to a number of different target cells. In physiological conditions, they are induced and released in basal amounts only in restricted microenvironments where they have paracrin...

journal_title：Clinical pharmacokinetics

authors： Bocci V

更新日期：1991-10-01 00:00:00

abstract：:Pregnancy is a specific dynamic state, and the potential usefulness of caring for a disorder in the fetus or the mother is now well established. Previously, pregnant women have been excluded from clinical trials, therefore only a few studies concerning evaluation of the pregestational metabolism or transplacental tran...

journal_title：Clinical pharmacokinetics

authors： Bourget P,Roulot C,Fernandez H

更新日期：1995-02-01 00:00:00

abstract：:Ketoprofen, a potent nonsteroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid class, has been used clinically for over 15 years in Europe, and has recently been introduced in the United States. Although it possesses a chiral centre, with only the S-enantiomer possessing beneficial pharmacological activi...

journal_title：Clinical pharmacokinetics

authors： Jamali F,Brocks DR

更新日期：1990-09-01 00:00:00

abstract：:20 routine patients with endogenous depression were investigated in a kinetic and 4 week treatment study. Steady-state plasma nortriptyline concentrations above 200 microgram/L were associated with a highly significant poorer therapeutic outcome. The correlations between the 24, 48 and 72 hour concentrations and stead...

journal_title：Clinical pharmacokinetics

authors： Montgomery SA,McAuley R,Montgomery DB,Braithwaite RA,Dawling S

更新日期：1979-03-01 00:00:00

abstract：:The disposition of simeprevir (SMV) in humans is characterised by cytochrome P450 3A4 metabolism and hepatic uptake by organic anion transporting polypeptide 1B1/3 (OATP1B1/3). This study was designed to investigate SMV plasma and liver exposure upon oral administration in subjects infected with hepatitis C virus (HCV...

journal_title：Clinical pharmacokinetics

authors： Snoeys J,Beumont M,Monshouwer M,Ouwerkerk-Mahadevan S

更新日期：2017-07-01 00:00:00

abstract：:Amiodarone is an iodinated benzofuran derivative with recognised antiarrhythmic activity in man. As yet, its pharmacokinetic behaviour has not been satisfactorily characterised. Specific and sensitive high-pressure liquid chromatographic methods have become available only recently and this partly explains the scarcity...

journal_title：Clinical pharmacokinetics

authors： Latini R,Tognoni G,Kates RE

更新日期：1984-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Preterm and term newborn infants show wide interindividual variability (IIV) in pharmacokinetic parameters of gentamicin. More extensive knowledge and use of predictive covariates could lead to faster attainment of therapeutic concentrations and a reduced need for concentration monitoring. This...

journal_title：Clinical pharmacokinetics

authors： Nielsen EI,Sandström M,Honoré PH,Ewald U,Friberg LE

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:The use of an opportunistic (also called scavenged) sampling strategy in a prospective pharmacokinetic study combined with population pharmacokinetic modelling has been proposed as an alternative strategy to conventional methods for accomplishing pharmacokinetic studies in neonates. However, th...

journal_title：Clinical pharmacokinetics

authors： Leroux S,Turner MA,Guellec CB,Hill H,van den Anker JN,Kearns GL,Jacqz-Aigrain E,Zhao W,TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) Consortiums.

更新日期：2015-12-01 00:00:00

abstract：:Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate ...

journal_title：Clinical pharmacokinetics

authors： Zandvliet AS,Schellens JH,Beijnen JH,Huitema AD

更新日期：2008-01-01 00:00:00

abstract：:Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kine...

journal_title：Clinical pharmacokinetics

authors： Kasichayanula S,Grover A,Emery MG,Gibbs MA,Somaratne R,Wasserman SM,Gibbs JP

更新日期：2018-07-01 00:00:00

abstract：:Cisapride, a prokinetic agent, has been used for the treatment of a number of gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults and children. Since 1993, 341 cases of ventricular arrhythmias, including 80 deaths, have been reported to the US Food and Drug Administration. Marketing of...

journal_title：Clinical pharmacokinetics

authors： Michalets EL,Williams CR

更新日期：2000-07-01 00:00:00

abstract：:Platelets contribute significantly to arterial-occlusive thrombosis, one of the major causes of death and disease throughout the world. Consequently, inhibiting platelet function is a potentially important therapeutic goal. Among agents that inhibit platelet function, ticlopidine shows a wide spectrum of antiplatelet ...

journal_title：Clinical pharmacokinetics

authors： Desager JP

更新日期：1994-05-01 00:00:00